TORONTO, Sept. 16 /PRNewswire/ - In a head to head comparison of Interface Biologics Inc. (IBI) Endexo Anti-thrombic additives versus commercially available heparin coated catheters, both products achieved significant reductions (88%) in thrombus versus the polyurethane (Carbothane(TM)) control (data on file).
"Due to the recent contamination, subsequent price increases, and safety issues for Heparin, catheter manufacturers are seeking alternative coatings for their products. Interface Biologics' Endexo(TM) anti-thrombic additives are non-drug polymers that have anti platelet properties. These polymers are compatible with a wide range of base polymers, and since they are an additive rather than a coating, afford ease of process manufacturing as well as provide both extra and intraluminal coverage, and are equivalent in thrombus reduction performance to commercially available coatings," stated Rich Sullivan, President and CEO of Interface Biologics.
The blood loop study was performed at the Medical Device Evaluation Center (MDEC) in Salt Lake City Utah. "Catheters with effective Endexo additives showed a significant reduction in thrombus versus a standard polyurethane control, and were not statistically different in antithrombotic efficacy versus a commercially available heparin coated catheter," stated Sivaprasad Sukavaneshvar, Ph.D., VP of MDEC.
About Interface Biologics Inc.
Interface Biologics is a biomaterials company located in Toronto, Canada. The company develops and manufactures novel anti-thrombic and anti-infective polymers used in medical devices for cardiovascular and urological applications.
|SOURCE Interface Biologics Inc.|
Copyright©2008 PR Newswire.
All rights reserved